Not Tagged
Not Tagged
['breast']
magistral lecture on the optimal duration of adjuvant et in hr+/her2- breast cancer by #asco23 small but long term risk of recurrence duration should be tailored based on the baseline risk (and tolerability) adherence is essential carry-over effect 
Medical Oncologist @IEOufficiale | Former Research Associate @MSKCancerCenter | @LaStatale Alumni | Interested in #bcsm #drugdevelopment  #bioinformatics #AI